Suppr超能文献

对于局限性前列腺癌行原发全腺体前列腺冷冻消融治疗前,BPH 的既往外科介入治疗是否会影响肿瘤学或功能结局?

Does prior surgical interventional therapy for BPH affect the oncological or functional outcomes after primary whole-gland prostate cryoablation for localized prostate cancer?

机构信息

Urology Department, University Hospital Cleveland Medical Center, Cleveland, OH, USA.

Urology Department, Al Kasr Al Aini Hospital, Cairo, Egypt.

出版信息

Prostate Cancer Prostatic Dis. 2021 Jun;24(2):507-513. doi: 10.1038/s41391-020-00306-z. Epub 2021 Jan 22.

Abstract

BACKGROUND

To assess whether prior interventional treatment for benign prostatic hyperplasia (BPH) influences oncologic or functional outcomes following primary whole-gland prostate cryoablation.

METHODS

Among 3831 men with prostate cancer who underwent primary whole-gland prostate cryoablation, we identified 160 with a history of prior BPH interventional therapy including transurethral needle ablation (n = 6), transurethral microwave thermotherapy (n = 9), or transurethral resection of the prostate (n = 145). Patients with a history of medically treated or unspecified BPH therapy were excluded from the study. Oncological and functional outcomes were compared between men with and without prior BPH interventional therapy.

RESULTS

In unadjusted analyses, prior interventional BPH therapy was associated with higher risks of postoperative urinary retention (17.5% vs. 9.6%, p = 0.001) and new-onset urinary incontinence (39.9% vs. 19.4%, p > 0.001) compared with no prior therapy. Interventional BPH therapy was not correlated with the risk of developing a rectourethral fistula (p = 0.84) or new-onset erectile dysfunction (ED) at 12 months (p = 0.08) following surgery. On multivariable regression, prior interventional BPH therapy was associated with increased risk of urinary retention (OR 1.9, 95%, p = 0.015) and new-onset urinary incontinence (OR 2.13, p < 0.001). The estimated 5 years Kaplan-Meier survival analysis showed no statistically significant difference (p = 0.3) in biochemical progression free survival between those who underwent interventional BPH therapy compared with those who did not. Local disease recurrence assessed by post cryoablation positive for-cause prostate biopsy showed no significant difference between the two groups (25.4% vs. 28.7%, p = 0.59).

CONCLUSIONS

Prior interventional BPH therapy did not affect the oncologic outcomes nor did it increase the risk of rectourethral fistula or ED in sexually performing patients prior to cryosurgery. Prior interventional BPH therapy was associated with increased risk of urinary retention and incontinence after primary whole-gland prostate cryoablation for prostate cancer.

摘要

背景

评估良性前列腺增生(BPH)的既往介入治疗是否会影响原发性全腺前列腺冷冻消融后的肿瘤学或功能结果。

方法

在 3831 名接受原发性全腺前列腺冷冻消融的前列腺癌患者中,我们确定了 160 名有 BPH 介入治疗史的患者,包括经尿道针消融(n=6)、经尿道微波热疗(n=9)或经尿道前列腺切除术(n=145)。患有经医学治疗或未指定的 BPH 治疗史的患者被排除在研究之外。比较了有和无既往 BPH 介入治疗的患者的肿瘤学和功能结果。

结果

在未调整的分析中,与无既往治疗相比,既往 BPH 介入治疗与术后尿潴留(17.5% vs. 9.6%,p=0.001)和新发尿失禁(39.9% vs. 19.4%,p>0.001)的风险增加相关。介入性 BPH 治疗与直肠尿道瘘的风险无关(p=0.84)或术后 12 个月新发勃起功能障碍(ED)(p=0.08)。多变量回归分析显示,既往 BPH 介入治疗与尿潴留风险增加相关(OR 1.9,95%,p=0.015)和新发尿失禁(OR 2.13,p<0.001)。估计的 5 年 Kaplan-Meier 生存分析显示,在接受介入性 BPH 治疗与未接受治疗的患者之间,无生化进展无病生存率无统计学差异(p=0.3)。冷冻消融后因原因前列腺活检阳性评估的局部疾病复发两组间无显著差异(25.4%vs.28.7%,p=0.59)。

结论

既往 BPH 介入治疗既不会影响肿瘤学结果,也不会增加冷冻手术前有性行为能力的患者发生直肠尿道瘘或 ED 的风险。既往 BPH 介入治疗与原发性全腺前列腺冷冻消融治疗前列腺癌后尿潴留和失禁的风险增加有关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验